Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.

International journal of epidemiology - 1 Dec 2017

Kobberø Lauridsen Bo, Stender Stefan, Frikke-Schmidt Ruth, Nordestgaard Børge G, Tybjærg-Hansen Anne

Abstract excerpt

Background: Results from randomized controlled trials (RCTs) have raised concern that the cholesterol-lowering drug ezetimibe might increase the risk of cancer. We tested the hypothesis that genetic variation in NPC1L1, mimicking treatment with ezetimibe, was associated with an increased risk of cancer. Methods: We included 67 257 individuals from the general population. Of these, 8333 developed cancer and 2057...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Denmark

Share to Ezetimibe

Share to Hypercholesterolemia

Share to Membrane Transport Proteins

Share to Mendelian Randomization Analysis

Share to Proportional Hazards Models

Source

Identifiers

PMID: 29106532
DOI: 10.1093/ije/dyx096

Genes

IVD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.PMID 29106532Read ↗

Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.Semantic proximity Read ↗

Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank.Semantic proximity Read ↗

Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study.Semantic proximity Read ↗

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.Semantic proximity Read ↗

Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization studySemantic proximity Read ↗

Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.Semantic proximity Read ↗

Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study.Semantic proximity Read ↗

Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.Semantic proximity Read ↗

Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.Semantic proximity Read ↗

Inactivating mutations in NPC1L1 and protection from coronary heart disease.Semantic proximity Read ↗

Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study.Semantic proximity Read ↗

The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug TargetingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.